Protara Therapeutics Inc at Guggenheim Healthcare Talks Oncology Day Transcript
Good morning. I'm Charles Zhu, one of the senior biotech analysts here at Guggenheim Securities. For our next session, we are joined by Protara, specifically Jackie and Jathin from Protara. I want to thank you very much for your participation at our conference today.
Questions & Answers
Perhaps just to kick us off, could you provide us with a brief overview of your company platform and pipeline, please?
Sure. Thanks for having us here today. So Protara is a New York City-based biopharm company. We take the approach of providing advanced scientific approaches to establish mechanisms. Our lead program is TARA-002. We are initially looking at that in non-muscle-invasive bladder cancer. TARA-002 is a immune potentiator that we are also looking at it in the rare pediatric disease, lymphatic malformations.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
